Applied Biotech Inc Watch

from S-4/A 9 pages Eleventh Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 19, 2010, Among New Binax, Inc., New Biosite Incorporated, Alere Newco, Inc., and Alere Newco II, Inc. ( the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4/A 9 pages Tenth Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 19, 2010, Among New Binax, Inc., New Biosite Incorporated, Alere Newco, Inc., and Alere Newco II, Inc. (The “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4/A 8 pages Ninth Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 1, 2010, Among Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc., and Scientific Testing Laboratories, Inc. ( the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4/A 8 pages Eighth Supplemental Indenture (This “Supplemental Indenture”), Dated as of March 1, 2010, Among Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc., and Scientific Testing Laboratories, Inc. (The “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Seventh Supplemental Indenture (This “Supplemental Indenture”), Dated as of January 29, 2010, Among Rmd Networks, Inc. ( the “New Guarantor”), Subsidiary of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Sixth Supplemental Indenture (This “Supplemental Indenture”), Dated as of January 29, 2010, Among Rmd Networks, Inc. (The “New Guarantor”), a Subsidiary of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Fifth Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 25, 2009, Among Free & Clear, Inc. and Tapesty Medical, Inc. (Collectively, the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-4 7 pages Fourth Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 25, 2009, Among Free & Clear, Inc. and Tapestry Medical, Inc. (Collectively, the “New Guarantors”), Subsidiaries of Inverness Medical Innovations, Inc. (Or Its Successor) (The “Issuer”), Inverness Medical Innovations, Inc., a Delaware Corporation, Each of the Guarantors (The “Existing Guarantors”) Under the Indenture Referred to Below, and the Bank of New York Mellon Trust Company, N.A., as Trustee Under the Indenture Referred to Below (The “Trustee”)

from S-3ASR 57 pages Inverness Medical Innovations, Inc., as Issuer, and , as Trustee Indenture Dated as of , 20

from S-4 34 pages $250,000,000 Aggregate Principal Amount Apogent Technologies Inc. 6½% Senior Subordinated Notes Due 2013 Purchase Agreement

from S-4 23 pages Registration Rights Agreement Dated as of June 2, 2003 by and Among Apogent Technologies Inc. as Issuer the Several Subsidiary Guarantors Parties Hereto as Guarantors And

from S-4 117 pages Indenture Among Apogent Technologies Inc., the Subsidiary Guarantors Parties Hereto and the Bank of New York, as Trustee 6½% Senior Subordinated Notes Due 2013 Dated as of June 2, 2003

from S-4 ~50 pages Purchase Agreement, Dated March 30, 2001